← 產業報告目錄

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-05-13頁數 469報告編號 MD9285

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The market for molecular infectious disease testing is expected to grow from USD 11.30 billion in 2026 to reach USD 19.09 billion by 2031, at a growth rate of 11.1%. The rapid advancement of molecular diagnostic techniques is a key driver of this market's growth. Innovations such as PCR and next-generation sequencing enhance the accuracy, speed, and efficiency of tests, making them more affordable and widely accessible. Furthermore, companies in the market are continuously developing advanced automated diagnostic systems. This leads to more precise and rapid detection of infectious diseases, resulting in improved patient outcomes and better monitoring of emerging pathogens. Consequently, healthcare providers can make more informed decisions regarding the application of molecular diagnostics for infectious diseases. “The laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period.” The market for molecular infectious disease testing can be divided into two main categories: laboratory tests and point-of-care tests, depending on the type of test. The laboratory tests segment is the fastest-growing due to its high accuracy and efficiency, as these tests can detect a wide range of pathogens. Laboratory tests, including PCR testing and sequencing-based testing, are particularly popular among hospitals and diagnostic laboratories because they provide precise disease identification. Significant advances in lab automation and high-throughput systems have enabled these tests to be performed efficiently. Additionally, there is a growing demand for comprehensive diagnostic tests that can detect multiple infections in a single test, further enhancing the preference for laboratory testing. With their reliable results and high diagnostic capabilities, laboratory tests offer an effective solution for detecting infectious diseases. “The multiplex testing segment accounted for the largest market share, by type, in 2025.” The global market for molecular infectious disease testing can be divided into two main segments: singleplex testing and multiplex testing. Among these, multiplex testing leads the market due to its ability to run multiple tests simultaneously, enabling the detection and differentiation of various pathogens in a single test. This capability not only saves time, money, and effort but also makes it the preferred choice for healthcare providers. Additionally, the rise in co-infections, the need for comprehensive diagnostic tests, and the demand for accurate results in shorter timeframes have all contributed to the growth of the multiplex testing market. “The Asia Pacific is the fastest-growing market for molecular infectious disease testing during the forecast period.” The global market for molecular infectious disease testing is segmented into the following regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries. The market is experiencing significant growth, particularly in the Asia Pacific region, driven by the high prevalence of infectious diseases in densely populated areas. There is a growing emphasis on early disease detection, which increases the demand for advanced diagnostic tools. Government and healthcare organizations are making substantial investments to enhance healthcare infrastructure, improve diagnostic facilities, and support research initiatives. Additionally, a focus on disease surveillance, outbreak management, and increased healthcare expenditure further contributes to the Asia Pacific region's significant role in the overall growth of the molecular infectious disease testing market. The breakdown of the profile of primary participants in the molecular infectious disease testing market is: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%) • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) The key players in the molecular infectious disease testing market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany). Research Coverage: This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point-of-care tests), by disease [respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector-borne diseases, hospital-acquired infections, and other infectious diseases], by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the molecular infectious disease testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. This report covers the competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem. Reasons to buy this report: The report will provide market leaders and newcomers with valuable insights into the revenue figures for the overall molecular infectious disease testing market and its subsegments. It will help stakeholders comprehend the competitive landscape, enabling them to better position their businesses and formulate effective go-to-market strategies. Additionally, the report will offer insights into the current market dynamics, highlighting key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (growing global infectious disease burden, advancements in molecular diagnostic technologies, growing funding for molecular testing, and growing awareness of early disease detection), restraints (lack of standardized reimbursement structures and high cost of instruments and consumables), opportunities (expansion potential across emerging economies, rising demand for point-of-care (POC) testing), and challenges (stringent and varying regulatory requirements, operational barriers and labor shortage challenges, and supply chain disruptions for reagents and kits) influencing the growth of the molecular infectious disease testing market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market. • Market Development: Comprehensive information about lucrative markets; the report analyzes the molecular infectious disease testing market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), and Abbott (US).
目錄 Table of Contents
1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 STUDY SCOPE 41 1.3.1 MARKETS COVERED & REGIONAL SCOPE 41 1.3.2 INCLUSIONS & EXCLUSIONS 42 1.3.3 YEARS CONSIDERED 42 1.4 CURRENCY CONSIDERED 43 1.5 STAKEHOLDERS 43 1.6 SUMMARY OF CHANGES 43 2 EXECUTIVE SUMMARY 45 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 47 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 50 3.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW 50 3.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 50 3.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2026 VS. 2031 51 3.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2026 VS. 2031 51 3.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2026 VS. 2031 52 3.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031 52 3.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2026 VS. 2031 53 3.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 4 MARKET OVERVIEW 54 4.1 INTRODUCTION 54 4.2 MARKET DYNAMICS 54 4.2.1 DRIVERS 55 4.2.1.1 Growing global infectious disease burden 55 4.2.1.2 Advancements in molecular diagnostic technologies 57 4.2.1.3 Growing funding for molecular testing 57 4.2.1.4 Growing awareness of early disease detection 58 4.2.2 RESTRAINTS 58 4.2.2.1 Lack of standardized reimbursement structures 58 4.2.2.2 High cost of instruments and consumables 59 4.2.3 OPPORTUNITIES 59 4.2.3.1 Expansion potential across emerging economies 59 4.2.3.2 Rising demand for point-of-care (POC) testing 60 4.2.4 CHALLENGES 61 4.2.4.1 Stringent and varying regulatory requirements 61 4.2.4.2 Operational barriers and labor shortage challenges 61 4.2.4.3 Supply chain disruptions for reagents and kits 62 4.3 UNMET NEEDS & WHITE SPACES 63 4.3.1 UNMET NEEDS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 63 4.3.2 WHITE SPACE OPPORTUNITIES 63 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 64 4.4.1 INTERCONNECTED MARKETS 64 4.4.2 CROSS-SECTOR OPPORTUNITIES 65 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66 4.5.1 KEY MOVES & STRATEGIC FOCUS 66 5 INDUSTRY TRENDS 67 5.1 PORTER’S FIVE FORCES ANALYSIS 67 5.1.1 BARGAINING POWER OF SUPPLIERS 68 5.1.2 BARGAINING POWER OF BUYERS 68 5.1.3 THREAT OF NEW ENTRANTS 68 5.1.4 THREAT OF SUBSTITUTES 68 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 69 5.2 MACROECONOMIC INDICATORS 69 5.2.1 INTRODUCTION 69 5.2.2 GDP TRENDS & FORECAST 69 5.3 SUPPLY CHAIN ANALYSIS 72 5.4 VALUE CHAIN ANALYSIS 73 5.5 ECOSYSTEM ANALYSIS 75 5.5.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75 5.6 PRICING ANALYSIS 76 5.6.1 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 76 5.6.2 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024–2026 77 5.7 TRADE ANALYSIS 78 5.7.1 IMPORT SCENARIO (HS CODE 3822) 78 5.7.2 EXPORT SCENARIO (HS CODE 3822) 79 5.8 KEY CONFERENCES & EVENTS, 2026–2027 80 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81 5.10 INVESTMENT & FUNDING SCENARIO 81 5.11 IMPACT OF 2025 US TARIFFS ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET 82 5.11.1 INTRODUCTION 82 5.11.2 KEY TARIFF RATES 82 5.11.3 PRICE IMPACT ANALYSIS 83 5.11.4 IMPACT ON REGIONS 83 5.11.4.1 North America 84 5.11.4.2 Europe 84 5.11.4.3 Asia Pacific 84 5.11.5 IMPACT ON END-USE INDUSTRIES 85 5.11.5.1 Diagnostic laboratories 85 5.11.5.2 Hospitals & clinics 85 5.11.5.3 Other end users 85 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86 6.1 KEY EMERGING TECHNOLOGIES 86 6.1.1 NEXT-GENERATION SEQUENCING 86 6.1.2 POLYMERASE CHAIN REACTION 86 6.2 COMPLEMENTARY TECHNOLOGIES 87 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS 87 6.2.2 LABORATORY INFORMATION SYSTEMS (LIS) & DIGITAL HEALTH INTEGRATION 87 6.3 ADJACENT TECHNOLOGIES 88 6.3.1 CRISPR-BASED DIAGNOSTICS 88 6.3.2 DIGITAL PCR (DPCR) 88 6.4 TECHNOLOGY/PRODUCT ROADMAP 89 6.5 PATENT ANALYSIS 90 6.5.1 LIST OF MAJOR PATENTS 91 6.6 FUTURE APPLICATIONS 92 6.7 IMPACT OF AI/GENERATIVE AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET 93 6.7.1 INTRODUCTION 93 6.7.2 TOP USE CASES & MARKET POTENTIAL 94 6.7.3 KEY COMPANIES IMPLEMENTING AI 94 6.7.4 FUTURE OF AI 95 7 SUSTAINABILITY & REGULATORY LANDSCAPE 96 7.1 REGIONAL REGULATIONS & COMPLIANCE 96 7.1.1 REGULATORY ANALYSIS 96 7.1.1.1 North America 96 7.1.1.1.1 US 96 7.1.1.1.2 Canada 96 7.1.1.2 Europe 96 7.1.1.2.1 Germany 97 7.1.1.2.2 UK 98 7.1.1.2.3 France 98 7.1.1.2.4 Italy 98 7.1.1.3 Asia Pacific 99 7.1.1.3.1 China 99 7.1.1.3.2 Japan 99 7.1.1.3.3 India 99 7.1.1.3.4 Australia 100 7.1.1.4 Latin America 100 7.1.1.4.1 Brazil 101 7.1.1.4.2 Mexico 101 7.1.1.5 Middle East 101 7.1.1.5.1 Africa 101 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 7.2 SUSTAINABILITY INITIATIVES 103 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 103 7.2.1.1 Eco-friendly initiatives 104 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 105 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 106 8.1 DECISION-MAKING PROCESS 106 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 106 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 106 8.2.2 BUYING CRITERIA 107 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 108 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109 8.5 MARKET PROFITABILITY 110 8.5.1 REVENUE POTENTIAL 110 8.5.2 COST DYNAMICS 110 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111 9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE 112 9.1 INTRODUCTION 113 9.2 REAGENTS & KITS 113 9.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH 113 9.3 INSTRUMENTS 117 9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH 117 9.4 SOFTWARE & SERVICES 121 9.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH 121 10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE 125 10.1 INTRODUCTION 126 10.2 MULTIPLEX TESTING 126 10.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH 126 10.3 SINGLEPLEX TESTING 130 10.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH 130 11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE 133 11.1 INTRODUCTION 134 11.2 LABORATORY TESTS 134 11.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH 134 11.3 POINT-OF-CARE TESTS 138 11.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 138 12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE 143 12.1 INTRODUCTION 144 12.2 RESPIRATORY INFECTIOUS DISEASES 144 12.2.1 INFLUENZA 148 12.2.1.1 Growing focus on faster diagnosis and control to propel market 148 12.2.2 TUBERCULOSIS 151 12.2.2.1 Rise in undiagnosed and untreated cases to promote growth 151 12.2.3 PHARYNGITIS 154 12.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth 154 12.2.4 NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS 156 12.2.4.1 Increasing reliance on advanced molecular diagnostic technologies to fuel growth 156 12.2.5 OTHER RESPIRATORY INFECTIOUS DISEASES 159 12.3 GASTROINTESTINAL INFECTIOUS DISEASES 162 12.3.1 HEPATITIS 165 12.3.1.1 Rising global incidence of infections to expedite growth 165 12.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES 168 12.4 SEXUALLY TRANSMITTED DISEASES 171 12.4.1 HUMAN IMMUNODEFICIENCY VIRUS 174 12.4.1.1 Increasing number of blood transfusions and blood donations to augment growth 174 12.4.2 HUMAN PAPILLOMAVIRUS 177 12.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market 177 12.4.3 CHLAMYDIA TRACHOMATIS 180 12.4.3.1 Increasing incidence of chlamydia to aid growth 180 12.4.4 NEISSERIA GONORRHOEAE 183 12.4.4.1 Increasing development of novel assays to boost market 183 12.4.5 SYPHILIS 186 12.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market 186 12.4.6 OTHER SEXUALLY TRANSMITTED DISEASES 189 12.5 HOSPITAL-ACQUIRED INFECTIONS 192 12.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET 192 12.6 VAGINITIS 195 12.6.1 INCREASING AWARENESS ABOUT WOMEN’S HEALTH TO BOLSTER GROWTH 195 12.7 MENINGITIS 198 12.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH 198 12.8 VECTOR-BORNE DISEASES 201 12.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET 201 12.9 BLOODSTREAM INFECTIONS & SEPSIS 205 12.9.1 HIGH BURDEN OF BLOODSTREAM INFECTIONS TO PROPEL MARKET 205 12.10 OTHER INFECTIOUS DISEASES 208 13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY 211 13.1 INTRODUCTION 212 13.2 POLYMERASE CHAIN REACTION 212 13.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH 212 13.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 217 13.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH 217 13.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 220 13.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET 220 13.5 IN SITU HYBRIDIZATION 223 13.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET 223 13.6 DNA MICROARRAYS 226 13.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH 226 13.7 OTHER TECHNOLOGIES 228 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER 231 14.1 INTRODUCTION 232 14.2 DIAGNOSTIC LABORATORIES 232 14.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET 232 14.3 HOSPITALS & CLINICS 235 14.3.1 RISING PATIENT VOLUMES TO CONTRIBUTE TO GROWTH 235 14.4 OTHER END USERS 238 15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION 240 15.1 INTRODUCTION 241 15.2 NORTH AMERICA 241 15.2.1 US 248 15.2.1.1 Presence of advanced healthcare infrastructure to augment growth 248 15.2.2 CANADA 252 15.2.2.1 Favorable government initiatives to fuel market 252 15.3 EUROPE 257 15.3.1 GERMANY 262 15.3.1.1 Increasing healthcare expenditure to advance growth 262 15.3.2 UK 266 15.3.2.1 Growing number of diagnostic centers to fuel market 266 15.3.3 FRANCE 271 15.3.3.1 Increasing demand for early disease diagnosis to augment growth 271 15.3.4 ITALY 275 15.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market 275 15.3.5 RUSSIA 280 15.3.5.1 Increasing access to quality healthcare to facilitate growth 280 15.3.6 SPAIN 284 15.3.6.1 Growing public health initiatives to boost market 284 15.3.7 REST OF EUROPE 289 15.4 ASIA PACIFIC 294 15.4.1 CHINA 300 15.4.1.1 Rising public access to modern healthcare to spur growth 300 15.4.2 JAPAN 304 15.4.2.1 Universal healthcare reimbursement policy to foster growth 304 15.4.3 INDIA 309 15.4.3.1 Increased private and public investments to bolster growth 309 15.4.4 AUSTRALIA 313 15.4.4.1 Growing investments for testing centers and treatment facilities to drive market 313 15.4.5 REST OF ASIA PACIFIC 318 15.5 LATIN AMERICA 322 15.5.1 BRAZIL 328 15.5.1.1 Growing focus on improving healthcare infrastructure to fuel market 328 15.5.2 MEXICO 332 15.5.2.1 Increasing accessibility and affordability of healthcare services to foster growth 332 15.5.3 REST OF LATIN AMERICA 337 15.6 MIDDLE EAST & AFRICA 341 15.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 341 15.7 GCC COUNTRIES 346 15.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET 346 16 COMPETITIVE LANDSCAPE 351 16.1 INTRODUCTION 351 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 351 16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 351 16.3 REVENUE ANALYSIS, 2023–2025 353 16.4 MARKET SHARE ANALYSIS, 2025 354 16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 354 16.4.2 US MARKET SHARE ANALYSIS, 2025 356 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 356 16.5.1 STARS 356 16.5.2 EMERGING LEADERS 357 16.5.3 PERVASIVE PLAYERS 357 16.5.4 PARTICIPANTS 357 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 358 16.5.5.1 Company footprint 358 16.5.5.2 Region footprint 358 16.5.5.3 Product & service footprint 359 16.5.5.4 Disease footprint 360 16.5.5.5 Test type footprint 361 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 361 16.6.1 PROGRESSIVE COMPANIES 361 16.6.2 RESPONSIVE COMPANIES 361 16.6.3 DYNAMIC COMPANIES 362 16.6.4 STARTING BLOCKS 362 16.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 363 16.6.5.1 Detailed list of key startups/SMEs 363 16.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 363 16.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 364 16.7 COMPANY VALUATION & FINANCIAL METRICS 364 16.7.1 FINANCIAL METRICS 364 16.7.2 COMPANY VALUATION 365 16.8 BRAND/PRODUCT COMPARISON 365 16.9 COMPETITIVE SCENARIO 366 16.9.1 PRODUCT LAUNCHES & APPROVALS 366 16.9.2 DEALS 367 16.9.3 EXPANSIONS 368 17 COMPANY PROFILES 369 17.1 KEY PLAYERS 369 17.1.1 DANAHER 369 17.1.1.1 Business overview 369 17.1.1.2 Products offered 370 17.1.1.3 Recent developments 372 17.1.1.3.1 Product approvals 372 17.1.1.3.2 Deals 373 17.1.1.4 MnM view 373 17.1.1.4.1 Key strengths 373 17.1.1.4.2 Strategic choices 373 17.1.1.4.3 Weaknesses & competitive threats 374 17.1.2 F. HOFFMANN-LA ROCHE LTD. 375 17.1.2.1 Business overview 375 17.1.2.2 Products offered 376 17.1.2.3 Recent developments 378 17.1.2.3.1 Product launches & approvals 378 17.1.2.3.2 Deals 379 17.1.2.3.3 Expansions 379 17.1.2.4 MnM view 379 17.1.2.4.1 Key strengths 379 17.1.2.4.2 Strategic choices 380 17.1.2.4.3 Weaknesses & competitive threats 380 17.1.3 BIOMÉRIEUX 381 17.1.3.1 Business overview 381 17.1.3.2 Products offered 382 17.1.3.3 Recent developments 384 17.1.3.3.1 Product launches & approvals 384 17.1.3.3.2 Deals 386 17.1.3.4 MnM view 386 17.1.3.4.1 Key strengths 386 17.1.3.4.2 Strategic choices 386 17.1.3.4.3 Weaknesses & competitive threats 386 17.1.4 HOLOGIC, INC. 387 17.1.4.1 Business overview 387 17.1.4.2 Products offered 388 17.1.4.3 Recent developments 389 17.1.4.3.1 Product approvals 389 17.1.4.4 MnM view 390 17.1.4.4.1 Key strengths 390 17.1.4.4.2 Strategic choices 390 17.1.4.4.3 Weaknesses & competitive threats 390 17.1.5 ABBOTT 391 17.1.5.1 Business overview 391 17.1.5.2 Products offered 392 17.1.5.3 Recent developments 394 17.1.5.3.1 Product approvals 394 17.1.5.3.2 Deals 394 17.1.5.4 MnM view 394 17.1.5.4.1 Key strengths 394 17.1.5.4.2 Strategic choices 394 17.1.5.4.3 Weaknesses & competitive threats 395 17.1.6 THERMO FISHER SCIENTIFIC INC. 396 17.1.6.1 Business overview 396 17.1.6.2 Products offered 397 17.1.6.3 Recent developments 398 17.1.6.3.1 Product launches 398 17.1.6.3.2 Deals 399 17.1.7 QIAGEN 400 17.1.7.1 Business overview 400 17.1.7.2 Products offered 401 17.1.7.3 Recent developments 402 17.1.7.3.1 Product launches & approvals 402 17.1.7.3.2 Deals 404 17.1.7.3.3 Expansions 404 17.1.8 REVVITY 405 17.1.8.1 Business overview 405 17.1.8.2 Products offered 407 17.1.9 GRIFOLS, S.A. 408 17.1.9.1 Business overview 408 17.1.9.2 Products offered 410 17.1.9.3 Recent developments 410 17.1.9.3.1 Product approvals 410 17.1.10 SEEGENE INC. 411 17.1.10.1 Business overview 411 17.1.10.2 Products offered 412 17.1.10.3 Recent developments 413 17.1.10.3.1 Product approvals 413 17.1.10.3.2 Deals 414 17.1.11 DIASORIN S.P.A. 415 17.1.11.1 Business overview 415 17.1.11.2 Products offered 416 17.1.11.3 Recent developments 418 17.1.11.3.1 Product approvals 418 17.1.11.3.2 Deals 419 17.1.12 SIEMENS HEALTHINEERS AG 420 17.1.12.1 Business overview 420 17.1.12.2 Products offered 421 17.1.12.3 Recent developments 422 17.1.12.3.1 Deals 422 17.1.12.3.2 Expansions 423 17.1.13 BECTON, DICKINSON AND COMPANY (BD) 424 17.1.13.1 Business overview 424 17.1.13.2 Products offered 425 17.1.13.3 Recent developments 426 17.1.13.3.1 Product approvals 426 17.1.13.3.2 Deals 427 17.1.13.3.3 Expansions 427 17.1.14 SD BIOSENSOR 428 17.1.14.1 Business overview 428 17.1.14.2 Products offered 429 17.1.14.3 Recent developments 430 17.1.14.3.1 Deals 430 17.2 OTHER PLAYERS 431 17.2.1 QUIDELORTHO CORPORATION 431 17.2.2 BRUKER 433 17.2.3 GENETIC SIGNATURES 435 17.2.4 CO-DIAGNOSTICS, INC. 436 17.2.5 VELA DIAGNOSTICS 437 17.2.6 MOLBIO DIAGNOSTICS PVT. LTD. 438 17.2.7 SAVYON DIAGNOSTICS 440 17.2.8 UNIOGEN OY 441 17.2.9 GENEOMBIO TECHNOLOGIES 442 17.2.10 ADVANCED MOLECULAR DIAGNOSTICS 443 17.2.11 ALTONA DIAGNOSTICS GMBH 445 17.2.12 GENEFIRST LIMITED 446 18 RESEARCH METHODOLOGY 447 18.1 RESEARCH DATA 447 18.2 SECONDARY DATA 448 18.2.1 LIST OF SECONDARY SOURCES 448 18.2.2 KEY DATA FROM SECONDARY SOURCES 449 18.2.3 PRIMARY DATA 449 18.2.3.1 List of primary sources 450 18.2.3.2 Key data from primary sources 450 18.2.3.3 Key industry insights 452 18.2.3.4 Breakdown of primary interviews 452 18.3 MARKET SIZE ESTIMATION 453 18.3.1 TOTAL MARKET SIZE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET 453 18.3.2 BOTTOM-UP APPROACH 453 18.3.2.1 Approach 1: Revenue estimation of key players 453 18.3.2.2 Approach 2: Study of annual reports and investor presentations 454 18.3.2.3 Approach 3: Primary interviews 454 18.3.2.4 Growth forecast 454 18.3.2.5 CAGR projections 455 18.3.3 TOP-DOWN APPROACH 455 18.4 DATA TRIANGULATION 456 18.5 RESEARCH ASSUMPTIONS 457 18.5.1 STUDY-RELATED ASSUMPTIONS 457 18.6 STUDY ASSUMPTIONS 457 18.6.1 PARAMETRIC ASSUMPTIONS 458 18.6.2 GROWTH RATE ASSUMPTIONS 458 18.7 RESEARCH LIMITATIONS 459 18.8 RISK ASSESSMENT 459 19 APPENDIX 460 19.1 DISCUSSION GUIDE 460 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 465 19.3 RELATED REPORTS 467 19.4 AUTHOR DETAILS 468
圖表清單 List of Tables & Figures
TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010 VS. 2023 VS. 2024 (MILLION PEOPLE) 56 TABLE 2 TOTAL TB INCIDENCE, 2024 56 TABLE 3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 68 TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 69 TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS 71 TABLE 6 EUROPE: MACROECONOMIC INDICATORS 71 TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS 71 TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS 72 TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 72 TABLE 10 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 77 TABLE 11 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024–2026 (USD) 77 TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78 TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 79 TABLE 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027 80 TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 82 TABLE 16 KEY PATENTS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2022–2026 91 TABLE 17 KEY COMPANIES IMPLEMENTING AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 95 TABLE 18 CLASSIFICATION OF IVD DEVICES IN EUROPE 97 TABLE 19 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 99 TABLE 20 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA 100 TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 107 TABLE 27 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 107 TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 108 TABLE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109 TABLE 30 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 113 TABLE 31 KEY REAGENTS & KITS AVAILABLE IN MARKET 114 TABLE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 33 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 34 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 35 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 36 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 37 KEY INSTRUMENTS AVAILABLE IN MARKET 118 TABLE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 39 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 40 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 41 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 42 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 43 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET 122 TABLE 44 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 45 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 46 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 47 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 48 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 49 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 126 TABLE 50 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET 127 TABLE 51 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 52 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 53 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 54 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 55 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 56 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET 130 TABLE 57 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 58 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 59 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 60 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 61 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 62 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 134 TABLE 63 KEY LABORATORY-BASED TESTS AVAILABLE IN MARKET 135 TABLE 64 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 65 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 66 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 67 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 68 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 69 KEY POINT-OF-CARE TESTS AVAILABLE IN MARKET 139 TABLE 70 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 71 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 72 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 73 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 74 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 75 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 144 TABLE 76 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 145 TABLE 77 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 78 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 79 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 80 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 81 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 82 KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET 149 TABLE 83 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 84 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 85 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 86 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 87 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 88 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET 152 TABLE 89 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 90 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 91 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 92 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 93 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 94 KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET 154 TABLE 95 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 96 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 97 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 98 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 99 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 100 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 101 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 102 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 103 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 104 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 105 OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 160 TABLE 106 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 107 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 108 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 109 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 110 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 111 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 112 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 113 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 114 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 115 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 116 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 117 KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET 166 TABLE 118 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 119 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 120 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 121 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 122 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 123 OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 169 TABLE 124 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 125 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 126 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 127 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 128 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 129 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 130 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 131 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 132 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 133 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 134 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 135 KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET 175 TABLE 136 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 137 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 138 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 139 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 140 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 141 KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET 178 TABLE 142 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 143 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 144 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 145 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 146 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 147 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET 180 TABLE 148 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 149 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 150 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 151 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 152 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 153 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 154 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEA, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 155 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 156 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 157 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 158 KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET 186 TABLE 159 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 160 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 161 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 162 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 163 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 164 OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 190 TABLE 165 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 166 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 167 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 168 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 169 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 170 KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET 193 TABLE 171 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 193 TABLE 172 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 173 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 174 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 175 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 176 KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET 195 TABLE 177 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2024–2031 (USD MILLION) 196 TABLE 178 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 179 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 180 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 181 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 182 KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET 199 TABLE 183 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY REGION, 2024–2031 (USD MILLION) 199 TABLE 184 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 185 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 186 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 187 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 188 KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 202 TABLE 189 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2024–2031 (USD MILLION) 203 TABLE 190 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 191 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 192 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 193 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 194 KEY BLOODSTREAM INFECTIONS & SEPSIS TESTING PRODUCTS AVAILABLE IN MARKET 205 TABLE 195 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY REGION, 2024–2031 (USD MILLION) 206 TABLE 196 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 197 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 198 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 199 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 200 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET 208 TABLE 201 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 202 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 203 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 204 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 205 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 206 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 212 TABLE 207 KEY POLYMERASE CHAIN REACTION-BASED TESTS AND DEVICES AVAILABLE IN MARKET 214 TABLE 208 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 209 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 210 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 211 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 212 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 213 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED TESTS AND DEVICES AVAILABLE IN MARKET 218 TABLE 214 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 218 TABLE 215 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 216 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 217 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 218 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 219 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 221 TABLE 220 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 221 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 222 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 223 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 224 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2024–2031 (USD MILLION) 224 TABLE 225 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 226 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 227 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 228 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 229 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET 226 TABLE 230 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY REGION, 2024–2031 (USD MILLION) 227 TABLE 231 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 232 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 233 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 234 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 235 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 229 TABLE 236 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 237 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 238 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 239 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 240 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 241 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 233 TABLE 242 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 243 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 244 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 245 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 246 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 236 TABLE 247 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 248 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 249 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 250 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 251 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 238 TABLE 252 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 253 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 254 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 255 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 256 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 241 TABLE 257 NORTH AMERICA: MACROECONOMIC INDICATORS 243 TABLE 258 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 259 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 244 TABLE 260 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 261 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 245 TABLE 262 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 245 TABLE 263 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 264 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 265 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 266 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 247 TABLE 267 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 248 TABLE 268 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 249 TABLE 269 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 270 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 249 TABLE 271 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 250 TABLE 272 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 273 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 274 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 275 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 252 TABLE 276 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 277 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 253 TABLE 278 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 279 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 254 TABLE 280 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 254 TABLE 281 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 282 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 283 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 284 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 256 TABLE 285 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 286 MACROECONOMIC INDICATORS FOR EUROPE 258 TABLE 287 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 258 TABLE 288 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 258 TABLE 289 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 290 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 259 TABLE 291 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 259 TABLE 292 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 293 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 294 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 295 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 261 TABLE 296 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 262 TABLE 297 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 263 TABLE 298 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 299 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 263 TABLE 300 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 264 TABLE 301 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 302 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 303 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 304 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266 TABLE 305 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 266 TABLE 306 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 267 TABLE 307 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 308 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 268 TABLE 309 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 268 TABLE 310 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 311 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 312 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 313 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 270 TABLE 314 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 271 TABLE 315 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 272 TABLE 316 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 317 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 272 TABLE 318 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 273 TABLE 319 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 320 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 321 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 322 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 275 TABLE 323 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 275 TABLE 324 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 276 TABLE 325 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 326 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 277 TABLE 327 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 277 TABLE 328 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 329 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 330 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 331 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 279 TABLE 332 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 333 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 281 TABLE 334 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 335 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 281 TABLE 336 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 282 TABLE 337 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 338 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 339 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 340 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 284 TABLE 341 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 342 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 285 TABLE 343 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 344 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 286 TABLE 345 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 286 TABLE 346 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 347 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 348 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 349 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 288 TABLE 350 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 351 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 290 TABLE 352 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 353 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 290 TABLE 354 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 291 TABLE 355 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 356 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 357 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 358 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 293 TABLE 359 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 293 TABLE 360 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 295 TABLE 361 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 362 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 296 TABLE 363 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 364 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 297 TABLE 365 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 297 TABLE 366 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 367 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 368 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 369 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 299 TABLE 370 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 300 TABLE 371 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 301 TABLE 372 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 373 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 301 TABLE 374 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 302 TABLE 375 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 376 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 377 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 378 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 304 TABLE 379 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 304 TABLE 380 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 305 TABLE 381 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 382 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 306 TABLE 383 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 306 TABLE 384 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 385 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 386 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 387 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 308 TABLE 388 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 309 TABLE 389 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 310 TABLE 390 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 391 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 310 TABLE 392 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 311 TABLE 393 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 394 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 395 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 396 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 313 TABLE 397 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 313 TABLE 398 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 314 TABLE 399 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 400 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 315 TABLE 401 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 315 TABLE 402 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 403 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 404 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 405 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 317 TABLE 406 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 407 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 319 TABLE 408 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 409 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 319 TABLE 410 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 320 TABLE 411 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 412 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 413 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 414 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 322 TABLE 415 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 322 TABLE 416 MACROECONOMIC INDICATORS FOR LATIN AMERICA 323 TABLE 417 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 324 TABLE 418 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 324 TABLE 419 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 420 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 325 TABLE 421 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 325 TABLE 422 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 423 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 424 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 425 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 327 TABLE 426 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 328 TABLE 427 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 329 TABLE 428 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 429 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 329 TABLE 430 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 330 TABLE 431 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 432 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 433 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 434 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 332 TABLE 435 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 332 TABLE 436 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 333 TABLE 437 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 438 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 334 TABLE 439 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 334 TABLE 440 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 441 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 442 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 443 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 336 TABLE 444 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 337 TABLE 445 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 338 TABLE 446 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 447 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 338 TABLE 448 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 339 TABLE 449 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 450 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 451 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 452 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 341 TABLE 453 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 341 TABLE 454 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 342 TABLE 455 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 456 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 343 TABLE 457 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 343 TABLE 458 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 459 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 460 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 461 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 345 TABLE 462 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 346 TABLE 463 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 347 TABLE 464 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 465 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 347 TABLE 466 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION) 348 TABLE 467 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 468 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 469 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 470 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 350 TABLE 471 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION) 350 TABLE 472 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2023−APRIL 2026 351 TABLE 473 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEGREE OF COMPETITION 354 TABLE 474 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: REGION FOOTPRINT 358 TABLE 475 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT 359 TABLE 476 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DISEASE FOOTPRINT 360 TABLE 477 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TEST TYPE FOOTPRINT 361 TABLE 478 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 363 TABLE 479 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 363 TABLE 480 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 364 TABLE 481 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 366 TABLE 482 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEALS, JANUARY 2023–APRIL 2026 367 TABLE 483 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: EXPANSIONS, JANUARY 2023–APRIL 2026 368 TABLE 484 DANAHER: COMPANY OVERVIEW 369 TABLE 485 DANAHER: PRODUCTS OFFERED 370 TABLE 486 DANAHER: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 372 TABLE 487 DANAHER: DEALS, JANUARY 2023–APRIL 2026 373 TABLE 488 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 375 TABLE 489 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 376 TABLE 490 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 378 TABLE 491 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–APRIL 2026 379 TABLE 492 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–APRIL 2026 379 TABLE 493 BIOMÉRIEUX: COMPANY OVERVIEW 381 TABLE 494 BIOMÉRIEUX: PRODUCTS OFFERED 382 TABLE 495 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 384 TABLE 496 BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026 386 TABLE 497 HOLOGIC, INC.: COMPANY OVERVIEW 387 TABLE 498 HOLOGIC, INC.: PRODUCTS OFFERED 388 TABLE 499 HOLOGIC, INC.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 389 TABLE 500 ABBOTT: COMPANY OVERVIEW 391 TABLE 501 ABBOTT: PRODUCTS OFFERED 392 TABLE 502 ABBOTT: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 394 TABLE 503 ABBOTT: DEALS, JANUARY 2023–APRIL 2026 394 TABLE 504 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 396 TABLE 505 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 397 TABLE 506 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 398 TABLE 507 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 399 TABLE 508 QIAGEN: COMPANY OVERVIEW 400 TABLE 509 QIAGEN : PRODUCTS OFFERED 401 TABLE 510 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 402 TABLE 511 QIAGEN: DEALS, JANUARY 2021–DECEMBER 2024 404 TABLE 512 QIAGEN: EXPANSIONS, JANUARY 2021–DECEMBER 2024 404 TABLE 513 REVVITY: COMPANY OVERVIEW 405 TABLE 514 REVVITY: PRODUCTS OFFERED 407 TABLE 515 GRIFOLS, S.A.: COMPANY OVERVIEW 408 TABLE 516 GRIFOLS, S.A.: PRODUCTS OFFERED 410 TABLE 517 GRIFOLS, S.A.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 410 TABLE 518 SEEGENE INC.: COMPANY OVERVIEW 411 TABLE 519 SEEGENE INC.: PRODUCTS OFFERED 412 TABLE 520 SEEGENE INC.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 413 TABLE 521 SEEGENE INC.: DEALS, JANUARY 2023–APRIL 2026 414 TABLE 522 DIASORIN S.P.A.: COMPANY OVERVIEW 415 TABLE 523 DIASORIN S.P.A.: PRODUCTS OFFERED 416 TABLE 524 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 418 TABLE 525 DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026 419 TABLE 526 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 420 TABLE 527 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 421 TABLE 528 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–APRIL 2026 422 TABLE 529 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–APRIL 2026 423 TABLE 530 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 424 TABLE 531 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 425 TABLE 532 BD: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 426 TABLE 533 BD: DEALS, JANUARY 2023–APRIL 2026 427 TABLE 534 BD: EXPANSIONS, JANUARY 2023–APRIL 2026 427 TABLE 535 SD BIOSENSOR: COMPANY OVERVIEW 428 TABLE 536 SD BIOSENSOR: PRODUCTS OFFERED 429 TABLE 537 SD BIOSENSOR: DEALS, JANUARY 2023–APRIL 2026 430 TABLE 538 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 431 TABLE 539 BRUKER: COMPANY OVERVIEW 433 TABLE 540 GENETIC SIGNATURES: COMPANY OVERVIEW 435 TABLE 541 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW 436 TABLE 542 VELA DIAGNOSTICS: COMPANY OVERVIEW 437 TABLE 543 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW 438 TABLE 544 SAVYON DIAGNOSTICS: COMPANY OVERVIEW 440 TABLE 545 UNIOGEN OY: COMPANY OVERVIEW 441 TABLE 546 GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW 442 TABLE 547 ADVANCED MOLECULAR DIAGNOSTICS: COMPANY OVERVIEW 443 TABLE 548 ALTONA DIAGNOSTICS GMBH: COMPANY OVERVIEW 445 TABLE 549 GENEFIRST LIMITED: COMPANY OVERVIEW 446 TABLE 550 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RISK ASSESSMENT 459 FIGURE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION & REGIONAL SCOPE 41 FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 45 FIGURE 3 GLOBAL MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2024–2031 45 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023–2025 46 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MOLECULAR INFECTIOUS DISEASE TESTING MARKET 47 FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2025 48 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49 FIGURE 8 RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET 50 FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50 FIGURE 10 MULTIPLEX TESTING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 11 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 12 STDS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 53 FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53 FIGURE 16 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 FIGURE 17 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 67 FIGURE 18 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS 73 FIGURE 19 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 20 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS 75 FIGURE 21 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81 FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 82 FIGURE 23 PATENT ANALYSIS FOR MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2016–DECEMBER 2025 91 FIGURE 24 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 94 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 106 FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 107 FIGURE 27 REGIONAL INCIDENCE OF HIV, 2023 174 FIGURE 28 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT 243 FIGURE 29 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT 295 FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023–2025 (USD MILLION) 353 FIGURE 31 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL) 354 FIGURE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (US) 356 FIGURE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 357 FIGURE 34 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT 358 FIGURE 35 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 362 FIGURE 36 EV/EBITDA OF KEY VENDORS 364 FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 365 FIGURE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: BRAND/PRODUCT COMPARISON FOR MOLECULAR INFECTIOUS DISEASE TESTING 365 FIGURE 39 DANAHER: COMPANY SNAPSHOT (2025) 370 FIGURE 40 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 376 FIGURE 41 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 382 FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 388 FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025) 392 FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 397 FIGURE 45 QIAGEN : COMPANY SNAPSHOT (2024) 401 FIGURE 46 REVVITY: COMPANY SNAPSHOT (2025) 406 FIGURE 47 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025) 409 FIGURE 48 SEEGENE INC.: COMPANY SNAPSHOT (2025) 412 FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 416 FIGURE 50 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 421 FIGURE 51 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 425 FIGURE 52 SD BIOSENSOR: COMPANY SNAPSHOT (2024) 429 FIGURE 53 RESEARCH DESIGN 447 FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 452 FIGURE 55 TOP-DOWN APPROACH 455 FIGURE 56 DATA TRIANGULATION 456

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們